XLV - Health Care Select Sector SPDR ETF
| Previous Close | 83.12 |
| Open | 82.77 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 3000 |
| Day's Range | 82.67 - 83.42 |
| 52 Week Range | 75.65 - 91.79 |
| Volume | 8,360,471 |
| Avg. Volume | 8,248,691 |
| Net Assets | 15.28B |
| NAV | 82.22 |
| PE Ratio (TTM) | N/A |
| Yield | 1.51% |
| YTD Return | -0.16% |
| Beta (3y) | 0.96 |
| Expense Ratio (net) | 0.14% |
| Inception Date | 1998-12-16 |
- Investopedia•6 days ago
Why J&J's Stock May Plunge 10%
Johnson & Johnson ( JNJ) shares may drop by about 10% based on an analysis of the technical chart. Should shares of the stock fall an additional 10%, it would mean Johnson and Johnson would have dropped by nearly 25% from its intraday high of around $148 on January 22. The technical setup continues to be negative in the stock, and it appears shares could fall from roughly $124.25 to about $111.33, a drop of 10.4%.
- MarketWatch•10 days ago
President Trump’s big drug price speech boosts pharma stocks
After weeks of build-up, drug industry watchers began to have real concerns about President Donald Trump’s big drug price speech on Friday. Many of the changes that were mentioned on Friday had been raised before by his administration, including drug price negotiation for certain government programs. Other proposals seemed unlikely to significantly bring down drug prices in the near-term, which Trump described as a goal of the plan.
- ETF Trends•12 days ago
6 Top Healthcare ETFs Rally as Trump Vows End to ‘Global Freeloading’
Healthcare stocks and top healthcare ETFs rallied Friday after President Donald Trump vowed to end to "global freeloading" that has allowed foreign countries to pay less on American-manufactured medicines. The Health Care Select Sector SPDR (XLV), the largest healthcare exchange traded fund, gained 1.5% Friday while the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, rose 2.7% and VanEck Vectors Generic Drugs ETF (GNRX) , which focuses on generic drug producers, added 2.2%.
- Yahoo Finance•12 days ago
Trump lets drug companies off the hook
After several delays, President Trump unveiled a plan to lower drug prices. Don't bank on it just yet.
- MarketWatch•12 days ago
Drug stocks slip, then swing back even higher after Trump unveils drug cost cutting plan
Healthcare stocks dipped after President Donald Trump started presenting his plan to cut prescription drug costs, then bounced sharply to trade even higher than pre-speech levels. The SPDR Health Care Select Sector ETF was up about 0.5% before Trump's speech began, then slid to be down 0.1% swinging higher to be up 1.1% at a new intraday high. Some changes to policy announced by Trump and Health and Human Services Secretary Alex Azar included drug price negotiation by government programs, an end to the "gag rule" on pharmacists--who cannot disclose if drug products can be bought for cheaper without using a health plan -- and disclosure of drugs' list prices pharmaceutical advertisements.
- Benzinga•12 days ago
Trump Strikes At PBMs, Insurers, Drugmakers With Plans To Lower Consumer Prices
Stocks representing the U.S. drug supply chain temporarily tumbled Friday as President Donald Trump proposed a broad plan to lower consumer health costs. Last year, it increased federal lobbying spending by 30 percent, and it may maintain such investments to prevent future follow-through.
- Market Realist•14 days ago
What Were the Hiring and Firing Trends in March?
The “Job Openings and Labor Turnover Survey” (or JOLTS) data for March was reported on May 8 and contains key information about job openings and total separations. The total number of separations include layoffs, retirements, and voluntary quits. As per the latest JOLTS report, the total separations for March came in at 5.3 million at a rate of 3.6% of the total workforce, an increase from the February reading of 5.2 million and 3.5%, respectively.
- Market Realist•15 days ago
FDA Approves JNJ’s Darzalex in Combination with VMP
Johnson & Johnson’s (JNJ) Darzalex injection is a CD-38 surface protein–directed antibody approved for the treatment of multiple myeloma. Today, JNJ announced that the US Food & Drug Administration (or FDA) approved Darzalex in combination with other drugs for the treatment of multiple myeloma, marking the fifth indication for which Darzalex has FDA approval.
- Market Realist•16 days ago
Analyzing Merck’s Revenue in 1Q18
Merck (MRK), one of the largest pharmaceutical companies worldwide, is classified into four business segments: Human Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company reported its 1Q18 results on May 1. During the quarter, Merck surpassed analysts’ EPS (earnings per share) estimate of $1, but missed their revenue estimate of $10.1 billion, reporting EPS of $1.05 on revenue of $10.0 billion.
- Market Realist•21 days ago
Which Sector Posted Major Job Gains in April?
The ADP March employment report was published on May 2. The report offered deeper insight into employment trends across different sectors in the US employment market. ADP and Moody’s Analytics prepared the monthly report.
Market Realist•22 days agoMounting Evidence of Inflation Firming Up
The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index4 jumped to a 14-year high and the Conference Board Consumer Confidence Index5 hovers near 17-year highs. This suggests that while times are good for most people, they have little desire to spend more in an economic expansion that is one of the longest on record. Households may save their gains from the Trump tax cuts, rather than spend in the economy, as the Commerce Department reports the savings rate ticked higher in February.
- Market Realist•22 days ago
Merck & Co.’s 1Q18 Earnings: Revenues up 6%
Headquartered in New Jersey, Merck & Co. (MRK) is one of the largest pharmaceutical companies worldwide. Its business is classified into four business segments: Human Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck & Co. beat Wall Street analysts’ estimates for earnings per share (or EPS) today but missed analysts’ estimates for revenues. It reported EPS of $1.05 on revenues of $10.0 billion for 1Q18, compared to estimates of EPS of $1.00 on revenues of $10.1 billion.
Market Realist•23 days agoJim Chanos: ‘Winter Is Coming to the US Health Care System’
Famed short seller Jim Chanos said in a recent interview, “winter is coming to the US health care system.” He has a bearish view on the healthcare sector and disclosed that he has a short position in Envision Healthcare (EVHC). EVHC stock price fell 2.2% on April 26 after Jim Chanos’s announcement about his short position in the stock.
- ETF Trends•24 days ago
Healthcare ETFs Lag Markets as Celgene Drags
Healthcare stocks and healthcare ETFs were among the worst performing areas of the S&P 500 Monday as Celgene (CELG) shares plunged in response to Morgan Stanley's projecting that a key experimental drug could be delayed. The Health Care Select Sector SPDR (XLV), the largest healthcare exchange traded fund, fell 0.7% Monday and was testing its short-term supporting trend line at the 50-day simple moving average. Additionally, the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, declined 1.1%.
- Market Realist•28 days ago
Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates
Bristol-Myers Squibb (BMY) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues in 1Q18. It reported EPS of $0.94 on revenues of $5.2 billion in 1Q18 today, compared to analysts’ estimates for EPS of $0.85 on revenues of $5.2 billion.
- Market Realist•last month
Another Indicator Signaling Rising Inflation
The US Bureau of Labor Statistics releases a monthly report that tracks price trends in wholesale markets. Industries from the manufacturing sector (XLI) are surveyed for changes in input prices, and this survey data is used to construct the PPI (Producer Price Index). The survey comprises questions on raw material prices, production levels, and finished goods.
- Market Realist•last month
3.2 Million Americans Quit Their Jobs in February
The “Job Openings and Labor Turnover Survey” (or JOLTS) data for February was reported on April 13, and it contains information about job openings and total separations. The total number of separations includes layoffs, retirements, and voluntary quitting. As per the latest JOLTS report, the total separations for February was 5.2 million at a rate of 3.5% of the total workforce and a decrease from the January reading of 5.9 million and 4.1%, respectively.
- Benzinga•last month
The Size Effect Is Working With Health Care ETFs
Investors solely focusing on large-cap health care stocks and exchange-traded funds this year are likely disappointed. Entering Tuesday, the Health Care Select Sector SPDR (NYSE: XLV), the largest ETF by assets tracking the sector, was up just 0.2 percent year-to-date. For investors willing to take on a little more risk with their health care investments, noteworthy is the fact that the size effect is working with health care stocks this year.
- Market Realist•last month
What to Expect from Johnson & Johnson’s 1Q18 Earnings
Johnson & Johnson's 1Q18 Earnings: What to Expect on April 17Johnson & Johnson’s estimates
- Barrons.com•last month
Medical-Device Makers Need Robust Results
As we approach another earnings season, medical-device companies look poised to report quarters in line with expectations. At least that's the warning from Morgan Stanley's David Lewis. He writes that first-quarter fundamentals look encouraging for the group, given a favorable utilization environment at the start of the year—and a more severe flu season than usual that could serve as another tailwind. Among large-caps in the space, Lewis says Intuitive Surgical (ISRG), Becton Dickinson (BDX), and Zimmer Biomet (ZBH) have a good chance of beating expectations.
Yahoo Finance Video•9 days agoMARKETS: Most investors don't expect recession in 2018
Yahoo Finance's Seana Smith speaks with Meridian Equity Partners' Jonathan Corpina about the possibility of a recession this year.
- CNBC Videos•12 days ago
Health care stocks soar, did Trump just give them the all...
After Trump's announcement, are health care stocks in the clear? With CNBC's Eamon Javers, CNBC's Melissa Lee, and the Fast Money traders, Tim Seymour, David Seaburg, Brian Kelly and Steve Grasso.
Yahoo Finance Video•13 days agoYahoo Finance Live: The Final Round - May 11th, 2018
Yahoo Finance's LIVE stock market coverage and analysis.
- Yahoo Finance Video•last month
Yahoo Finance Live: Midday Movers - Apr 17th, 2018
Yahoo Finance's LIVE stock market coverage and analysis.
